

1 **Research Articles**

2

3 Title:

4 **Evaluation of performance of two SARS-CoV-2 Rapid whole-blood finger-stick IgM-IgG**
5 **Combined Antibody Tests**

6

7

8 **Authors**

9 Thierry Prazuck¹, Mathilda Colin¹, Susanna Giachè¹, Camélia Gubavu¹, Aymeric Seve¹,
10 Vincent Rzepecki¹, Marie Chevereau-Choquet¹, Catherine Kiani¹, Victor Rodot¹, Elsa
11 Lionnet¹, Laura Courtellemont², Jérôme Guinard², Gilles Pialoux³ and Laurent Hocqueloux¹

12 ¹ Department of infectious and tropical diseases, CHR Orléans, 14 Avenue de l'Hôpital, 45
13 067, Orléans (France)

14 ² Department of virology, CHR Orleans, 14 Avenue de l'Hôpital, 45 067, Orléans (France)

15 ³ : Department of infectious diseases, Hôpital Tenon, Assistance Publique des Hôpitaux de
16 Paris, Paris, France

17

18 **Corresponding Author**

19 Thierry Prazuck
20 Service des maladies infectieuses
21 CHR Orléans, 14 avenue de l'hôpital, 45 067 Orléans, France
22 thierry.prazuck@chr-orleans.fr

23

24

25 **Abstract**

26 **Background**

27 The SARS-CoV-2 virus is responsible for the infectious respiratory disease called COVID-19
28 (COronaVirus Disease). In response to the growing COVID-19 pandemic, Rapid Diagnostic
29 Tests (RDTs) have been developed to detect specific antibodies, IgG and IgM, to SARS-CoV-
30 2 virus in human whole blood. We conducted a real-life study to evaluate the performance of
31 two RDTs, COVID-PRESTO® and COVID-DUO®, compared to the gold standard, RT-PCR.

33 **Methods**

34 RT-PCR testing of SARS-Cov-2 was performed from nasopharyngeal swab specimens
35 collected in adult patients visiting the infectious disease department at the hospital (Orléans,
36 France). Fingertip whole blood samples taken at different time points after onset of the disease
37 were tested with RDTs. The specificity and sensitivity of the rapid test kits compared to test of
38 reference (RT-PCR) were calculated.

40 **Results**

41 Among 381 patients with symptoms of COVID-19 who went to the hospital for a diagnostic,
42 143 patients were RT-PCR negative. Results of test with RDTs were all negative for these
43 patients, indicating a specificity of 100% for both RDTs.

44 In the RT-PCR positive subgroup (n=238), 133 patients were tested with COVID-PRESTO®
45 and 129 patients were tested with COVID-DUO® (24 patients tested with both). The further the
46 onset of symptoms was from the date of collection, the greater the sensitivity. The sensitivity
47 of COVID-PRESTO® test ranged from 10.00% for patients having experienced their 1st
48 symptoms from 0 to 5 days ago to 100% in patients where symptoms had occurred more than
49 15 days before the date of tests. For COVID-DUO® test, the sensitivity ranged from 35.71%
50 [0-5 days] to 100% (> 15 days).

52 **Conclusion**

53 COVID-PRESTO® and DUO® RDTs turned out to be very specific (none false positive) and to
54 be sensitive enough after 15 days from onset of symptom. These easy to use IgG/IgM
55 combined test kits are the first ones allowing a screening with capillary blood sample, by typing
56 from a finger prick. These rapid tests are particularly interesting for screening in low resource
57 settings.

58
59 **Keywords:** SARS-CoV-2; COVID-19; Rapid Diagnostic Test; IgG; IgM

60 Introduction

61 At the end of 2019, a pneumonia of unknown cause detected in Wuhan, China was first
62 reported to the WHO Country Office in China. On January 9th, 2020, the Chinese health
63 authorities and the World Health Organization (WHO) officially announced the discovery of a
64 novel coronavirus, first named 2019-nCoV, then officially termed SARS-CoV-2. This virus,
65 belonging to the coronavirus family, differs from the viruses SARS-CoV, responsible for the
66 SARS outbreak in 2003, and MERS-CoV, responsible for an ongoing outbreak that began in
67 2012 in the Middle East.

68 The SARS-CoV-2 virus is responsible for the infectious respiratory disease called COVID-19
69 (COronaVirus Disease). This infection mainly results in pneumonia and upper/lower
70 respiratory tract infection. The symptoms of COVID-19 infection appear after an incubation
71 period of approximately 5.2 days [1]. The most common symptoms at onset of COVID-19
72 illness are fever, cough, and fatigue, but others include headache, sore throat, and even acute
73 respiratory distress syndrome, leading to respiratory failure.

74 Since the emergence of COVID-19 in China at the end of last year, the SARS-CoV-2 virus has
75 caused a large global outbreak and has become a major worldwide public health issue. The
76 WHO has declared this outbreak a global health emergency at the end of January 2020. On
77 April 12th, 2020, the World Health Organization (WHO) announced that the total global deaths
78 from COVID-19 has surpassed 100 000. Globally, by April 28th, 2020, 2,892,688 cases of
79 COVID-19 have been confirmed and 210,193 patients have died. An estimated 1.7 billion
80 people have been ordered to remain at home as governments take extreme measures to
81 protect their populations.

82 Due to the rapid spread and increasing number of COVID-19 cases caused by this new
83 coronavirus SARS-CoV-2, rapid and accurate detection of virus and/or disease is increasingly
84 vital to control the sources of infection and prevent the progression of the disease.

85 Besides the main priority, which is finding an efficient treatment, one of the most important
86 research questions targets the diagnosis of COVID-19. Currently, the real-time RT-PCR assay
87 is the gold-standard method to detect SARS-CoV-2 [2]. This diagnostic test aims at detecting
88 nucleic acid (RNA) from SARS-CoV-2 in upper and lower respiratory specimens such as
89 nasopharyngeal or oropharyngeal swabs or broncho-alveolar lavage.

90 In response to the growing COVID-19 pandemic, serology tests have been developed to detect
91 specific antibodies, IgG and IgM, to SARS-CoV-2 virus in human whole blood, serum or
92 plasma. Two kinds of serologic tests are currently available [3]: quantitative ones with
93 antibodies titration by enzyme-linked immunosorbent assay (ELISA) and qualitative ones with
94 Rapid Diagnostic Tests (RDTs), easy-to-use devices mainly based on lateral flow
95 chromatographic immunoassays.

96 COVID-PRESTO[®] and COVID-DUO[®] are two RDTs products with CE marking which are
97 marketed by AAZ-LMB. In line with the recommendations of the health authorities, we
98 conducted a real-life study to evaluate the performance of both AAZ COVID 19 IgM/IgG RDTs
99 compared to the gold standard, RT-PCR.

100

101 **Methods and Materials**

102 **Ethics Approval**

103 The study was approved by the local Ethics Committee on March 17th 2020, and informed
104 consent was obtained from each participant.

105 **Study population**

106 The study population consisted of adult patients visiting the infectious disease department
107 (Centre Hospitalier Regional Orléans, France) from March, 18th, 2020 to April 10th, 2020. This
108 department receives patients whose symptoms, such as headache, fatigue, fever or
109 respiratory signs suggest a COVID infection, and for whom a diagnosis is requested. Date of
110 onset of symptoms as declared by the patient and age were collected at inclusion. According
111 to severity of disease, patients RT-PCR positive were either hospitalized in the infectious
112 diseases ward, only devoted to treat COVID-19 infected patients, or invited to have regular
113 medical visits in the outpatient consultation. Fingertip blood samples were performed at various
114 stages of the follow-up, even after clinical cure, in order to collect samples from convalescent
115 patients.

116 **Specimen collection**

117 Nasopharyngeal (NP) swab specimens were collected from patients by trained surveillance
118 officers. A polyester-tipped flexible aluminum-shafted applicator (Microtest M4RT, Remel) was
119 inserted into one of the nostrils until resistance was felt at the nasopharynx, then rotated 180
120 degrees and withdrawn. After swabbing, the swab applicator was cut off, and each absorbent
121 swab was placed into a vial containing 3 mL of viral transport media. Vials were immediately
122 shipped via a triple packaging system to the virology unit located in the same building of the
123 hospital, then stored if necessary at 4°C for up to 24 hours until testing.

124 For whole blood samples taken at the fingertip, a lancet was used to prick the side of the
125 fingertip to let a large drop of suspended blood form. This blood sample was collected with a
126 10 µl capillary micropipette that filled automatically. The sample was then expelled by
127 squeezing the micropipette bulb to deposit the blood on the appropriate well of the test
128 cassette. Retesting was performed in a same patient only if the previous test was negative.

129 **Real-time RT-PCR assays for the detection of SARS-CoV-2**

130 RT-PCR testing of SARS-CoV-2 was performed in Unit of Virology, CHR Orléans. Nucleic acid
131 extraction was performed with automated EZ1 (Qiagen). Specific real-time RT-PCR assays
132 targeting two RNA-dependent RNA polymerases (IP2 and IP4) and E genes were used to
133 detect the presence of SARS-CoV-2 following the instructions in the protocols of the Institut
134 Pasteur and Corman et al., respectively [4] [5]. Amplification was performed on an ABI 7900
135 Sequence Detection System (Applied Biosystem).

136 **Rapid diagnostic tests to be assessed**

137 The SARS-CoV-2 IgG/IgM antibody test kits, COVID-PRESTO[®] and COVID-DUO[®], are
138 targeting on the antibodies specific to N-protein of SARS-CoV-2. They are manufactured and
139 marketed by AAZ-LMB.


140 Tests were conducted at the site by clinical staff, physicians or nurses, according to
 141 manufacturers' instructions. Health workers involved in the study received a two-hours training
 142 session for each type of test prior to the beginning of the study.

143 Both COVID-PRESTO[®] and COVID-DUO[®] are lateral flow immune-chromatographic assays
 144 (Figs 1 and 2). These tests use anti-human IgM antibody (test line IgM), anti-human IgG
 145 antibody (test line IgG) and rabbit IgG (control line C) immobilized on a nitrocellulose strip. The
 146 Conjugate (recombinant COVID-19 antigens labeled with colloidal gold) is also integrated into
 147 the strip. When a specimen is added to the sample well, followed by assay buffer, IgM and IgG
 148 antibodies, if present, will bind to COVID-19 conjugates forming an antigen-antibodies
 149 complex.

150 This complex migrates through nitrocellulose membrane by capillary action. When the complex
 151 meets the line of the corresponding immobilized antibody (anti-human IgM and/or anti-human
 152 IgG), the complex is trapped, forming a burgundy colored band which confirms a reactive test
 153 result. The result has to be read within 10 minutes by two independent operators. When the
 154 control line is the only to be burgundy, the sample is negative. If the control line does not
 155 appear, the test is invalid and should be repeated with a new cassette.


156

157 **Fig 1. Interpretation of results for COVID-PRESTO[®]**



158

159 **Fig 2. Interpretation of results for COVID-DUO[®]**



160

161

162 **Data Analysis**

163 Population were described in terms of %, mean, standard deviation, range and median
164 values.

165 The test data was analyzed in the Department of Infectiology. The specificity and sensitivity
166 of the rapid test kits compared to test of reference (RT-PCR) were calculated according to
167 the following formulas:

168 Specificity (%) = $100 \times [\text{Negative} / (\text{Negative} + \text{Positive})]$.

169 Sensitivity (%) = $100 \times [\text{Positive} / (\text{Positive} + \text{Negative})]$

170 Confidence intervals for sensitivity were produced with the Wilson score method [6].

171


172 **RESULTS**

173 Overall, 381 patients with symptoms of COVID-19 who went to the hospital for a diagnostic,
 174 were included in the study.

175 RT-PCR was performed in all patients: 62.47% were positive (n=238). Based on these results,
 176 two sub-groups were defined: 143 patients with negative and 238 patients with positive RT-
 177 PCR results (Fig 3).

178

179 **Fig 3. Number of samples screened with RT-PCR and Rapid Diagnostic Tests (RDT)**



180

181 In the negative RT-PCR subgroup, the mean age was 48.20 years (SD: 17.00; range 19-72),
 182 median at 46 years. Among these patients, 72 and 71, respectively, were tested with COVID-
 183 PRESTO® and COVID-DUO® tests. All results were negative indicating a specificity of 100%
 184 for both RDTs.

185 In the RT-PCR positive subgroup, the mean age of patients was 53.68 years ± 20.18 (median
 186 54; range 19-96).

187 For COVID-PRESTO® test, fingertip blood samples were collected from 133 patients, only
 188 once (n=133) or at two (n=16) or three different times (n=1). Overall 150 samples used to
 189 evaluate the sensitivity of this test. The further the onset of symptoms was from the date of
 190 collection, the greater the sensitivity (Table 1): 69.23% [CI95%: 53.58-81.43%] for patients
 191 with symptoms that occurred from 11 to 15 days before the date of test and 100% [CI95%:
 192 92.59-100%] in patients who experienced first symptoms more than 15 days before the test.
 193 Interestingly, among patient with samples collected at two different times, an elderly woman,

194 75 years of age, with multiple cancer treated by chemotherapy was negative at Day 15 and
 195 positive at Day 19, both for IgM and IgG.

196

197 **Table 1. Evaluation of the sensitivity of the COVID-PRESTO® test**

Number of days since the onset of symptoms

	0-5 days	6-10 days	11-15 days	>15 days
Positive	2	25	27	48
Negative	18	18	12	0
Sensitivity [CI 95%]	10.00% [2.79-30.10%]	58.14% [4.33-71.62%]	69.23% [53.58-81.43%]	100% [92.59-100%]

198

199 For COVID-DUO® test, 129 patients were screened with one (n=129), two (n=4) or three
 200 samples (n=1) at different times. The sensitivity was assessed based on 134 conducted tests
 201 (Table 2). The sensitivity ranged from 35.71% [CI95%: 16.34-61.24%] for patients having
 202 experienced their 1st symptoms from 0 to 5 days ago, to 100% [CI95%: 89.85-100%] in patients
 203 where symptoms had occurred more than 15 days before the date of tests.

204

205 **Table 2. Evaluation of the sensitivity of the COVID-DUO® test**

Number of days since the onset of symptoms

	0-5 days	6-10 days	11-15 days	>15 days
Positive	5	23	36	34
Negative	9	19	8	0
Sensitivity [CI 95%]	35.71% [16.34-61.24%]	54.76% [39.95-68.78%]	81.82% [68.04-90.49%]	100% [89.85-100%]


206

207

208 When considering the distribution of IgM+ and IgG+ patterns among patients with a positive
 209 RDT test, the IgM were the first antibodies to be detected and were systematically present in
 210 the few positive patients with an onset of symptoms from 0 to 5 days ago (n=2 in COVID-
 211 PRESTO® population; n=5 in COVID-DUO®). The IgM appeared first and stayed prevalent until
 212 15 days after viral infection then IgG became more frequent (Figs 4 and 5).

213


214 **Fig 4. Patients with a positive COVID-PRESTO[®] test: distribution of IgM+ and IgG+ patterns**
215



216

217

218 **Fig 5. Patients with a positive COVID-DUO[®] test: distribution of IgM+ and IgG+ patterns**



219

220

221 DISCUSSION

222 This real-life study aimed at evaluating the performance of two Rapid Diagnostic Tests (RDT)
223 designed to detect SARS-CoV-2 antibodies IgG and IgM from a fingertip whole blood sample.
224 We investigated the quick detection approach of COVID-PRESTO® and COVID-DUO® in
225 comparison with RT-PCR testing.

226 The performance analysis was conducted in 381 patients. The results showed that the
227 sensitivity of both RDTs increases with the duration from symptoms onset, reaching 100% in
228 patients experiencing first symptoms of COVID-19 more than 15 days ago. The specificity of
229 both RDTs was found to be 100%, no false positive results having been obtained.

230 The sensitivity and specificity of such strip assays based on immuno-chromatography have
231 been recently estimated in several studies performed with venous blood samples. In a
232 retrospective study, serum from 179 patients was used to detect SARS-CoV-2 IgG/IgM
233 antibodies [7]. Patients were stratified by the time from symptoms onset to sample collection:
234 0-7 days, 8-15 days and >15 days. Sensitivities of 18.8%, 100% and 100% were reported,
235 respectively, for the three groups with very few patients (n=8) in the 8-15 days group. The
236 specificity was 77.8%, 50% and 64.3%, respectively, with numerous reported cases of “false
237 positives”. In a second prospective study, the sensitivity of a strip assay investigated in 86
238 patients was 11.1%, 92.9% and 96.8% at the early stage (1–7 days after onset), intermediate
239 stage (8–14 days after onset), and late stage (more than 15 days), respectively [8]. In another
240 prospective study with 397 PCR confirmed COVID-19 patients and 128 negative patients, the
241 performance of another lateral flow immunoassay test product was evaluated [9]. Overall, the
242 sensitivity was 88.66% and the specificity 90.63%. Although this study was performed with
243 more patients (n=525) than in our study, the evaluation of performance was limited because
244 no information was collected about the period over which each patient had experienced
245 symptoms at the time of blood sample collection. Furthermore, to date, no performance study
246 has been reported based on capillary blood samples.

247 Although COVID-PRESTO® and COVID-DUO® are only qualitative tests, the reported
248 sensitivities and specificities are closed to those of quantitative assays such as enzyme linked
249 immunosorbent assay (ELISA). Zhao et al. collected blood samples from 173 patients with a
250 confirmed infection with SARS-CoV-2 (acute respiratory infection syndromes and/or
251 abnormalities in chest CT images accompanied by detectable SARS-CoV-2 RNA) at different
252 times after onset of COVID-19: <7 days since onset (early phase), 8-14 days after onset
253 (middle phase) and 13-39 days after onset (later phase) [10]. The detection of IgM and IgG
254 against SARS-CoV-2 in this study was performed using ELISA kits. The sensitivities of IgM
255 assays were 38.3%, 73.3% and 94.3% successively, among samples from patients in early,
256 middle and later phases, respectively. For IgG, the values were 38.3%, 54.1% and 79.8%.
257 Interestingly, the RNA test (RT-PCR on samples from the respiratory tract) had the highest
258 sensitivity (66.7%) in the early phase of illness while RNA was only detectable in 45.5% of
259 samples of day 15-39. From a methodological point of view, the performance study presented
260 here was more robust to that of Zhao et al. because the positive population used as reference
261 to evaluate the sensitivity of RDTs was only based on positive RT-PCR results, and not a mix
262 between syndromes, imaging findings and RNA detection.

263 The results of the present study highlight two major points. Firstly, as for the assessed RDT,
264 the sensitivity of ELISA tests increases with the duration from symptom onset. Moreover, we
265 showed that direct antibody typing with whole blood is as sensitive as immunoassay performed
266 with serum in a retrospective way. Secondly, these diagnostic tests (either qualitative or
267 quantitative) can help to diagnose a past infection after elimination of the virus by the immune
268 system. Thus, combining RT-PCR and antibody detection allows to largely diagnose COVID-
269 19 people regardless of the delay between infection and diagnosis.

270 Currently, the extent and the time kinetics of humoral response against SARS-CoV-2 are not
271 known. It is widely accepted that IgM is usually the first responded antibody providing the first
272 line of defense during viral infections, prior to the generation of adaptive, high affinity IgG
273 responses serving as the more robust long term immunity. We were not able to study the
274 humoral response at the individual level because too few patients could have been tested more
275 than once. At the population level, the patterns of IgM/IgG results obtained for positive tests
276 with COVID-DUO[®] made it possible to perceive the switch between the first production of IgM
277 and the later onset of IgG. This coincided with our observations with the COVID-PRESTO[®].
278 One of the reasons could lie on the high proportion (90%) of false negative results during the
279 early phase of infection, directly linked to the low titers of antibodies during the first days after
280 infection. Both IgM and IgG titers were found to be low or undetectable 4 days after infection
281 [11] [12]. It was also shown that the presence of antibodies was less than 40% among patients
282 within 1 week since onset, and rapidly increased to 94.3% (IgM) and 79.8% (IgG) from day-15
283 after onset [10]. The presence of IgM and IgG antibodies against SARS-CoV-2 within 2 weeks
284 from the onset of symptoms was confirmed by others [13] [11]. Recently, in 41 COVID-19
285 patients confirmed by RT-PCR, it was shown by chemiluminescent immunoassay that the
286 median time of seroconversion was 11 days after disease onset for IgG and 14 days for IgM
287 [14]. The time required to have detectable levels of antibodies explains the poor performance
288 (sensitivity 18.4%) reported for a COVID-19 IgM/IgG Rapid test evaluated in patients admitted
289 to the emergency room [15]. The authors concluded that the Rapid Test lateral Flow Immuno
290 Assay was not recommended for triage of patients with suspected COVID-19. Indeed, COVID-
291 19 cannot be excluded at an early stage when viral serological testing is negative. Although
292 slightly lower than the specificity obtained for COVID-PRESTO[®] and –DUO[®], the specificity at
293 early stages was high (91.7%), preventing false positive diagnoses.

294 This study has several limitations. Firstly, the date of onset of symptoms related to SARS-CoV-
295 2 infection implied recall of facts from memory. This recall bias could lead to some imprecise
296 classification when stratifying the samples by days between onset of symptoms and date of
297 blood samples. Secondly, few patients with a negative serology could have been re-tested with
298 a second blood sample. In these conditions, we were not able to study the dynamics of
299 seroconversion on individual level. Thirdly, there were still negative tests in RT-PCR positive
300 patients up to 15 days after onset. The reasons are multiple and include the relatively low titers
301 of antibody in the early stages of infection as reported by others [16] and the difference in
302 individual immune response antibody production. Lastly, the strength of antibody response
303 depends on several factors, including age, severity of disease, and certain conditions like
304 immunodeficiency disorders. Therefore it would have been interesting to stratify the population
305 depending on immune health. Indeed, we had few subjects with profound immunosuppression
306 who were still negative 15 days after onset. We know, however, that seroconversion could
307 occur later in such patients [17] [18]. Future studies should focus on seroconversion from Day

308 15 to Day 30 in highly immunocompromised patients infected with COVID-19. However, the
309 highly immunosuppressed patient in this study was well documented to seroconvert between
310 day 15 and day 19, which provides reassurance of the performance of the RDT, even in this
311 population.

312 Whatever these limitations, COVID-PRESTO[®] and DUO[®] RDTs turned out to be very specific
313 (none false positive) and to be sensitive enough after 15 days from onset of symptom. These
314 easy to use IgG/IgM combined test kits are the first ones allowing a screening with capillary
315 blood sample, by typing from a finger prick blood sample. The tests are simple, qualitative,
316 visually interpretable, and give a result within 15 minutes. A positive serology allows to
317 determine whether a person has already been infected by SARS-CoV-2. Serologic tests will
318 be needed to assess the response to vaccine candidates and to map levels of immunity in
319 communities. These rapid tests are particularly interesting for low resource settings such as at
320 the bedside or any other locations where lab tests are less obvious.

321

322

323 **Contributions**

324 TP, JG, GP and LH were responsible for the study design, data interpretation, literature
325 research, and writing of the manuscript. MC, SG, AS, VR, MCC, CK, VR, EL and LC performed
326 the serological testing. TP, MC, CG and LH were responsible for the clinical management,
327 patient recruitment, and data collection. TP, MC JG and LH collected and analyzed the data

328

329 **Acknowledgments**

330 The authors would like to thank the technical staff of the Department of Infectious diseases for
331 excellent assistance. Furthermore, the authors thank Angèle Guilbot of Clinact, France for
332 providing medical writing support/editorial support in accordance with Good Publication
333 Practice (GPP3) guidelines.

334

335 **Declaration of interest**

336 The authors report no conflicts of interest. The authors alone are responsible for the content
337 and the writing of the paper.

338

339 **Funding**

340 Rapid Diagnostic Tests were provided free of charge by AAZ-LMB.

341

342

343 **REFERENCES**

- 344 1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease
345 (COVID-19) outbreak. *Journal of Autoimmunity*. 2020;109: 102433.
346 doi:10.1016/j.jaut.2020.102433
- 347 2. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al.
348 *Severe acute respiratory syndrome-related coronavirus*: The species and its viruses – a
349 statement of the Coronavirus Study Group. *Microbiology*; 2020 Feb.
350 doi:10.1101/2020.02.07.937862
- 351 3. World Health Organization 2020. Advice on the use of point-of-care immunodiagnostic
352 tests for COVID-19. Scientific brief. 8 April 2020. Available from:
353 [https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19)
354 [immunodiagnostic-tests-for-covid-19](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19). Accessed 9 May 2020.
- 355 4. World Health Organization 2020 - Real-time RT-PCR assays for the detection of SARS-
356 CoV-2, Institut Pasteur, Paris. Available from: [https://www.who.int/docs/default-](https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2)
357 [source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-](https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2)
358 [pasteur-paris.pdf?sfvrsn=3662fcb6_2](https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2). Accessed 9 May 2020.
- 359 5. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of
360 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. 2020;25.
361 doi:10.2807/1560-7917.ES.2020.25.3.2000045
- 362 6. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of
363 seven methods. *Statistics in Medicine*. 1998;17: 857–872. doi:10.1002/(SICI)1097-
364 0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E
- 365 7. Liu Y, Liu Y, Diao B, Ren F, Wang Y, Ding J, et al. Diagnostic Indexes of a Rapid
366 IgG/IgM Combined Antibody Test for SARS-CoV-2. *Infectious Diseases (except*
367 *HIV/AIDS)*; 2020 Mar. doi:10.1101/2020.03.26.20044883
- 368 8. Pan Y, Li X, Yang G, Fan J, Tang Y, Zhao J, et al. Serological immunochromatographic
369 approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. *Journal of*
370 *Infection*. 2020. doi:10.1016/j.jinf.2020.03.051
- 371 9. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and Clinical Application of A
372 Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. *Journal*
373 *of Medical Virology*. 2020. doi:10.1002/jmv.25727
- 374 10. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel
375 coronavirus disease 2019. *Clin Infect Dis*. 2020 Mar 28. pii: ciaa344. doi:
376 10.1093/cid/ciaa344. [Epub ahead of print]
- 377 11. Haveri A, Smura T, Kuivanen S, Österlund P, Hepojoki J, Ikonen N, et al. Serological
378 and molecular findings during SARS-CoV-2 infection: the first case study in Finland,
379 January to February 2020. *Eurosurveillance*. 2020;25. doi:10.2807/1560-
380 7917.ES.2020.25.11.2000266
- 381 12. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
382 Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020.
383 doi:10.1038/s41586-020-2196-x
- 384 13. Nisreen M.A. Okba, Marcel A. Müller, Wentao Li, Chunyan Wang, Corine H.
385 GeurtsvanKessel, Victor M. Corman, et al. Severe Acute Respiratory Syndrome

- 386 Coronavirus 2–Specific Antibody Responses in Coronavirus Disease 2019 Patients.
387 Emerging Infectious Disease journal. 2020;26. doi:10.3201/eid2607.200841
- 388 14. Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of IgG and IgM antibodies
389 against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical
390 Infectious Diseases. 2020. doi:10.1093/cid/ciaa489
- 391 15. Cassaniti I, Novazzi F, Giardina F, Salinaro F, Sachs M, Perlini S, et al. Performance of
392 VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in
393 acute patients referring to emergency room department. Journal of Medical Virology.
394 2020. doi:10.1002/jmv.25800
- 395 16. Du Z, Zhu F, Guo F, Yang B, Wang T. Detection of antibodies against SARS-CoV-2 in
396 patients with COVID-19. Journal of Medical Virology. 2020. doi:10.1002/jmv.25820
- 397 17. Brousseau N, Murphy DG, Gilca V, Larouche J, Mandal S, Tedder RS. Acute hepatitis
398 B virus infection with delayed appearance of hepatitis B core antibody in an
399 immunocompromised patient: a case report. Journal of Medical Case Reports. 2017;11.
400 doi:10.1186/s13256-017-1264-9
- 401 18. Lehrnbecher T, Koehl U, Wittekindt B, Bochennek K, Tramsen L, Klingebiel T, et al.
402 Changes in host defence induced by malignancies and antineoplastic treatment:
403 implication for immunotherapeutic strategies. The Lancet Oncology. 2008;9: 269–278.
404 doi:10.1016/S1470-2045(08)70071-8
- 405